News&Media

Gongwin’s Compassionate treatment is approved to go ahead

Gongwin’s Compassionate treatment is approved to go ahead

Emerging market stock Gongwin-KY (6617) announced yesterday (24th) that the compassionate treatment using new drug PTS100 of its subsidiary Gongwin Biopharm Co., Ltd. for the treatment of melanoma patients was approved by Taiwan’s Ministry of Health and Welfare.

Gongwin expressed that Gongwin Biopharm recently received an official letter from the Ministry of Health and Welfare, stating that certain physician from a medical center in the northern part of Taiwan submitted an application to the Ministry of Health and Welfare proposing to use PTS100 in accordance with provisions in Article 3-1 of the " Regulations on Human Trials" for treatment of melanoma. The Ministry of Health and Welfare agrees to this application in principle.

Gongwin pointed out that, in this case of melanoma, a variety of domestic drugs available domestically were used for treatment but to no avail. Therefore, the medical center submitted a project application to the Ministry of Health and Welfare, in accordance with the provisions of the " Regulations on Human Trials." According to the relevant provisions of the " Regulations on Human Trials ", this type of treatment needs to be submitted by a doctor, reviewed and approved by the hospital's Institutional Review Board (IRB), and then submitted to the Ministry of Health and Welfare for approval.

The institutional investors pointed out that, in addition to the implementation of liver cancer phase II clinical trials in Taiwan, Gongwin is also actively collaborations with physicians from domestic medical centers to conduct various clinical explorations and treatments to expand the scope of various cancer treatments. Following the implementation on the case of metastatic liver tumor in January this year, the scope is now expanded to melanoma.

Even though Gongwin-KY is an overseas company listed in Taiwanese emerging market, the company’s operating headquarters is established in Taipei City, and its R&D center is located in Wugu District, New Taipei City. It has already applied to be stationed in the Hsinchu Biomedical Science Park, and the application is already approved.